Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 11/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633270 | 0.89 | TP53 (0.46) | PLK1RXFP1DAOTP53 | |
| SCHEMBL25633268 | 0.84 | TP53 (0.41) | PLK1RXFP1TP53GAA | |
| SCHEMBL25633263 | 0.81 | NPC1 (0.46) | PLK1TP53GAA | |
| SCHEMBL25633271 | 0.78 | PLK1 (0.36) | PLK1DAOGAA | |
| SCHEMBL25633260 | 0.78 | PIK3R1 (0.39) | PLK1DAOGAA | |
| SCHEMBL25633269 | 0.76 | TP53 (0.52) | RXFP1TP53GAA | |
| SCHEMBL25360546 | 0.75 | LMNA (0.36) | GAA | |
| SCHEMBL25633343 | 0.72 | TP53 (0.58) | RXFP1TP53 | |
| SCHEMBL25633279 | 0.69 | TP53 (0.62) | RXFP1TP53 | |
| SCHEMBL21419936 | 0.64 | MAPT (0.41) | PLK1RXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | PLK1 2452/4885RXFP1 456/4885DAO 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.